Vertex Pharmaceuticals (NASDAQ: VRTX) has encountered significant challenges this year, resulting in a 2% decline in its stock price, contrasting with a 9% increase in the S&P 500. Despite these issues, the company may present an attractive investment opportunity for growth over the next five years, suggesting that investors should remain optimistic about its potential.
